Ultragenyx Pharma (RARE) PT Lowered to $45 at Citi
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $26.49 +0.42%
Rating Summary:
21 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
21 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $45.00 (from $66.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Tactical Resources completes Plum merger, set for Nasdaq debut
- Lithium Ionic Corp (LTH:CN) PT Lowered to Cdn$2.50 at Desjardins
- Diversified Royalty Corp (DIV:CN) (BEVFF) PT Lowered to Cdn$4.75 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
